• Bioscience Health Innovations posted a net loss of USD 229,907 for quarter ended March 31, 2026, swinging from net income of USD 426,798 a year earlier.
• Revenue fell 38.83% to USD 750,946, with management citing adjustments in sales channels and a rescheduled order from a major co-brand customer.
• General administrative expense climbed to USD 625,809 from USD 433,561, while consulting expense rose to USD 89,694 from USD 35,786 on work tied to an application to move from OTC markets to a senior exchange.
• Cash used in operating activities widened to USD 552,107 from cash provided of USD 328,309, while cash and working capital ended period at USD 1,145,005 and USD 1,549,089.
• Management said it is offering a private placement to accredited investors to raise up to USD 1 million, then plans to prepare and file Form 1-A with SEC, while adding two independent directors ahead of a Nasdaq uplist.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioscience Health Innovations Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001185185-26-001775), on May 11, 2026, and is solely responsible for the information contained therein.